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A b s t r a c t
Introduction: Data on the role of androgens as potential mediators of in-
creasing cardiovascular risk in women at midlife are controversial. The aim 
of the study was to analyze the relationship of free testosterone (FT) and sex 
hormone binding globulin (SHBG) with blood pressure and subclinical organ 
damage and metabolic syndrome (MS) in middle aged hypertensive women.
Material and methods: One hundred and fifty-two women with newly diag-
nosed arterial hypertension were included in the study. In all subjects blood 
pressure measurements were performed as well as echocardiographic ex-
amination with left ventricular structure and function assessment (GE Vivid 
7.0), carotid ultrasound with measurement of intima-media thickness (IMT), 
and carotid-femoral pulse wave velocity (PWV) measurement (Sphygmocor). 
A  fasting blood sample was taken to measure glucose and lipid concentra-
tions. Serum testosterone and SHBG were measured. Free testosterone was 
calculated according to the Vermeulen formula. Metabolic syndrome was de-
fined following the International Diabetes Federation (IDF) recommendations.
Results: Free testosterone was significantly higher and SHBG lower in wom-
en with MS independently of menopausal status. The odds ratio of MS per 
quartile increment in FT after adjustment for covariates was 2.06 (95% CI: 
1.16–3.65). There was no correlation between FT, SHBG and blood pressure. 
Free testosterone was associated with decreased left ventricular diastolic 
function (E/A ratio β = –0.19, p = 0.05) and subclinical atherosclerosis (IMT 
β = 0.34, p = 0.009), but not arterial stiffness. 
Conclusions: Free testosterone and SHBG independently of menopause sta-
tus are related to MS. Free testosterone is associated with worse metabolic 
profile, subclinical atherosclerosis and impaired diastolic function of the left 
ventricle.
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Introduction
Cardiovascular disease affects men and women differently, with wom-
en having later onset of disease, with rapid increase of cardiovascular 
risk with the onset of menopause. Hypertension is a major cardiovascu-
lar risk factor possibly explaining the excessive cardiovascular morbidity 
and mortality in postmenopausal women. During the transition from the 
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premenopause to postmenopause state, many 
women also experience weight gain and central 
fat deposition [1]. It is likely that the enhanced 
cardiovascular risk in postmenopausal women is 
associated with metabolic syndrome (MS). Met-
abolic syndrome carries a  fourfold higher risk of 
cardiovascular events in females than in males [2]. 
In a hypertensive female this risk may be partial-
ly mediated through an increased prevalence of 
hypertension-induced preclinical cardiovascular 
damage. Research has recently refocused interest 
on the cardiovascular role of androgens, shifting 
attention away from estrogens toward testoster-
one and sex hormone-binding globulin (SHBG) 
as potential mediators of increasing cardiovascu-
lar risk in women at midlife. In postmenopausal 
women androgens are unopposed by estrogen 
levels, but whether it plays a role in cardiometa-
bolic risk modulation remains unclear.
Since androgen replacement therapy is in-
creasingly being used for the treatment of sexual 
dysfunction and decreased well-being in post-
menopausal women, its impact on lipid and met-
abolic parameters related to cardiovascular health 
should be studied thoroughly.
The aim of the study was to analyze the rela-
tionship of free testosterone (FT) and SHBG with 
blood pressure, hypertension-related subclinical 
organ damage and MS in hypertensive perimeno-
pausal women.
Material and methods
Study group
We recruited consecutive female patients aged 
40–60, who were referred to the Outpatient Clinic 
of the 1st Department of Cardiology and Hyperten-
sion by general physicians with newly diagnosed, 
untreated mild to moderate hypertension to un-
dergo 24-h ambulatory blood pressure monitor-
ing (ABPM). Diagnosis of hypertension by general 
physicians was based on the office blood pressure 
measurements taken on two separate visits using 
semiautomatic, validated, oscillometric devices 
in accordance with European Society of Cardiol-
ogy (ESC) and European Society of Hypertension 
(ESH) guidelines [3]. Hypertension was defines 
as average blood pressure equal to or exceeding 
140 mm Hg systolic or 90 mm Hg diastolic. In all 
subjects 24-h ABPM (SpaceLabs 90210, SpaceLabs 
Inc., Redmond, Washington, USA), with blood 
pressure readings every 15 min during the day 
and every 20 min during the night, was performed 
in the Outpatient Clinic to confirm the diagnosis 
of sustained hypertension. Patients with surgical 
menopause, women using hormone replacement 
therapy or oral contraceptives, women with chron-
ic kidney disease (defined as estimated glomerular 
filtration rate < 60 ml/min/1.73 m2) and patients 
with diabetes mellitus were excluded from the 
study. The study group consisted of 152 women. 
All participants underwent a clinical assessment; 
a detailed history was taken using a standardized 
questionnaire and a physical examination with an-
thropometric measurements was performed. The 
definition of postmenopausal status was based 
on two criteria: self-reported menstrual character-
istics (last menstruation > 1 year ago) confirmed 
by blood follicle stimulating hormone level (FSH) 
> 40 IU/l. The study protocol was approved by the 
local ethics committee (KBET/51/B/2007).
Methods
All blood samples were taken during the follicu-
lar phase of the menstrual cycle in premenopausal 
women and arbitrarily in postmenopausal women. 
The levels of FSH and estradiol were measured us-
ing MEIA kits, Abbott (sensitivity 1 ng/ml for estra-
diol and 0.5 mIU/ml for FSH). Serum testosterone 
and SHBG were measured using the electroche-
miluminescence immunoassay and Cobas immu-
noassay analyzers (Roche Diagnostics), with limits 
of detection at 0.087 nmol/l for testosterone and 
0.800 nmol/l for SHBG. Concentrations of free and 
bioavailable testosterone were derived from total 
testosterone, SHBG and albumin concentration, 
calculated according to the Vermuelen formula 
[4]. Routine laboratory methods were applied for 
measurement of basic biochemical parameters. 
Metabolic syndrome was defined following the 
modified criteria of the International Diabetes 
Federation proposed in 2009 [5]. As all subjects 
included in the study were hypertensive, to diag-
nose MS at least two of the following criteria had 
to be fulfilled: waist circumference > 80 cm; ele-
vated triglyceride level (≥ 1.7 mmol/l); decreased 
HDL cholesterol (< 1.3 mmol/l); and/or elevated 
fasting glucose concentration (≥ 100 mg%).
Assessment of subclinical organ damage
Echocardiographic measurements were per-
formed by one experienced observer, using a dig-
ital ultrasound system: GE Vivid 7 equipped with 
a  3.5-MHz transducer (General Electric Vingmed 
Ultrasound, Horten, Norway). As a  measure of 
systolic function, dimensional fractional short-
ening was computed. For evaluation of diastolic 
function, mitral inflow velocities were recorded 
with pulsed-wave Doppler sonography. Carotid ar-
tery ultrasound with a high-resolution ultrasound 
scanner was performed with a  high frequency 
(7 MHz) linear array transducer (GE Vivid 7 Gener-
al Electric Vingmed Ultrasound, Horten, Norway). 
The automated intima-media thickness (IMT) 
package from Vivid 7 was used. The IMT was mea-
Association of free testosterone and sex hormone binding globulin with metabolic syndrome and subclinical atherosclerosis but not blood 
pressure in hypertensive perimenopausal women
Arch Med Sci 3, June / 2016 523
sured in the far wall of the common carotid artery 
at a 1 cm distance from the carotid bifurcation in 
a single frame during the end-diastolic phase. The 
presence of at least one carotid atherosclerotic 
plaque (defined as a focal thickening greater than 
1.5 mm) or diffuse intima-media thickening (the 
average common carotid wall thickness exceeding 
0.9 mm) was taken as evidence of vascular alter-
ations. 
The measurement of carotid-femoral pulse wave 
velocity (PWV) was performed using the Sphygmo-
Cor system (AtCor Medical, Sydney, Australia; Mod-
el MM3; software version 6.31). Detailed methodol-
ogy of the assessment of subclinical organ damage 
has been published elsewhere [6].
Statistical analysis
Statistica 10.0 software was used for data 
management and statistical analysis (StatSoft, 
Statistica 10.0, Tulsa, Oklahoma, USA). The Sha-
piro-Wilk test was used to check the normality of 
distribution of analyzed variables. As the distribu-
tions of SHBG and FT concentrations were skewed, 
these values were log-transformed in order to im-
prove normality for statistical testing. Continuous 
variables were compared by analysis of variance 
(ANOVA), using Student’s t -test for dual compari-
sons. Analysis of categorical data was carried out 
by the χ2 test. Linear regression and multiple lin-
ear regression models were used to test the in-
dependent role of sex hormones and cardiomet-
abolic risk factors and parameters of subclinical 
organ damage. Logistic regression models were 
performed in order to determine the odds ratio of 
the MS by quartiles of endogenous sex hormone 
levels. Models were adjusted for age. Since body 
mass index (BMI) is strongly associated with sex 
hormones as well as many MS components, anal-
yses were repeated with additional adjustment for 
BMI as a  continuous variable to control for con-
founding. The last model also included as a covari-
ate menopausal status or estrogen concentration.
Results
Study group characteristics
Mean age of the study group was 51.0 ±3.5 
years. The prevalence of MS was 41% (63 patients). 
Characteristics of the study group in reference to 
the presence of MS are presented in Table I. 
Relationship between FT, SHBG and MS
Women with MS, in both the premenopaus-
al and postmenopausal group, had significantly 
higher FT concentration and lower SHBG con-
centration (Table II). Sex hormone binding glob-
ulin was significantly lower in postmenopausal 
compared to premenopausal women. There were 
no significant differences in FT concentration be-
tween pre- and postmenopausal females (Table II).
Analyzing the relationship between FT, SHBG 
and MS components, we found that the strongest 
association with FT was present for HDL choles-
terol (Pearson’s correlation coefficient: r = –0.54, 
p < 0.001), waist circumference (r = 0.24, p = 0.03) 
and triglyceride concentration (r = 0.27, p = 0.02). 
Body mass index showed a  positive association 
with FT, which was of borderline statistical signif-
icance (r = 0.22, p = 0.05). We did not observe 
a correlation between FT and fasting glucose con-
centration (r = 0.02, p = 0.81) or blood pressure 
(r = 0.20, p = 0.08). Similarly, SHBG did not correlate 
with blood pressure values (r = –0.09, p = 0.45), 
but correlated significantly with HDL cholesterol 
(r = 0.49, p < 0.001), BMI (r = –0.37, p < 0.001), 
waist circumference (r = –0.32, p = 0.006) and tri-
glyceride concentration (r = –0.23, p = 0.04). 
The differences in MS components across quar-
tiles of FT and SHBG are summarized in Tables III 
and IV. The increase in number of MS components 
was accompanied by higher concentration of FT 
(Figure 1). An opposite relationship was detected 
for SHBG concentration (Figure 2). 
The odds ratio of MS per quartile increment in 
FT was 2.44 (95% CI: 1.43–4.14), and after adjust-
ment for age, menopausal status and BMI it was 
still significant 2.06 (95% CI: 1.16–3.65). The odds 
ratio of MS per quartile decrement in SHBG was 
2.18 (95% CI: 1.29–3.68), but after adjustment for 
age and BMI it lost its significance (adjusted odds 
ratio 1.68, 95% CI: 0.97–3.05).
Relationship between FT, SHBG and target 
organ damage
Multivariate linear regression analysis revealed 
that FT independently of age, BMI, systolic blood 
pressure and menopausal status was inversely 
related to the parameter of left ventricular dia-
stolic function (mitral inflow velocities E/A  ratio) 
and subclinical atherosclerosis assessed by ca-
rotid IMT thickness (Table V). Including parame-
ters of lipid profile in the multivariate analysis 
did not change the results. Left ventricular mass 
(LVM) and parameters of arterial stiffness were 
not related to testosterone concentration in the 
examined group (LVM indexed to height r = 0.05, 
p = 0.63; PWV r = 0.04, p = 0.75).
We observed a significant negative correlation 
between SHBG and LVM (correlation coefficient 
for LVM indexed to height: r = –0.30, p = 0.007), 
and diastolic function (E/A: r = 0.33, p = 0.002) 
but not with vascular phenotypes (IMT: r = –0.13, 
p = 0.24, PWV: r = –0.15, p = 0.21). In multivari-
ate linear regression analysis the relationship be-
tween SHBG and LVM was mainly BMI dependent. 
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Diastolic function was age and BMI related, and in 
the model including these variables SHBG was ex-
cluded from factors significantly influencing E/A. 
Discussion
The main finding of our study is a  significant 
association of FT with MS, subclinical athero-
sclerosis and left ventricular diastolic function in 
middle aged women, independent of menopaus-
al status. While hyperandrogenism is associated 
with the MS and increased risk of cardiovascular 
disease in premenopausal women with polycystic 
ovary syndrome [7], the relation between endog-
enous androgens and cardiovascular disease in 
postmenopausal women is complex. Serial mea-
surements of testosterone in postmenopausal 
women showed that testosterone levels decrease 
after the menopause transition along with es-
tradiol levels, but increased slowly with age in 
9-year observation, such that by 70 years of age, 
the androgen levels were similar to levels found 
in premenopausal women [8]. The difference be-
tween pre- and postmenopausal women was that 
the androgen levels were unopposed by estrogen 
levels in postmenopausal women. Independent-
ly of menopausal status, in our study population 
increased FT was related to higher risk of MS. 
Among MS components the critical variables for 
this finding were the waist circumference, HDL 
concentration and triglyceride concentration. On 
the basis of our results we suggest that FT and 
Table I. Clinical characteristics of the study group with reference to the presence of metabolic syndrome. Data are 
expressed as mean values ± standard deviations (SD)
Parameter Metabolic syndrome P-value
No
N = 89
Yes
N = 63
Age [years] 50.9 ±2.4 51.1 ±3.2 NS
Postmenopausal, n (%) 41 (46.1) 32 (50.8) NS
Body weight [kg] 69.2 ±9.7 75.5 ±8.4 < 0.001
Body height [cm] 162.9 ±5.8 162.6 ±4.8 NS
BMI [kg/m2] 26.0 ±3.2 28.5 ±2.6 < 0.001
Waist circumference [cm] 83.6 ±8.4 89.8 ±7.1 < 0.001
Office SBP [mm Hg] 151.0 ±12.6 163.4 ±20.0 0.03
Office DBP [mm Hg] 89.0 ±10.6 93.4 ±12.3 NS
Heart rate [/min] 73.4 ±9.2 78.1 ±10.3 0.05
24-h ABPM SBP [mm Hg] 132.9 ±6.5 133.9 ±8.5 NS
24-h ABPM DBP [mm Hg] 81.2 ±6.8 82.8 ±9.2 NS
Glucose [mmol/l] 4.9 ±0.4 5.3 ±0.6 < 0.001
Total cholesterol [mmol/l] 5.4 ±0.9 5.7 ±0.9 < 0.0001
LDL cholesterol [mmol/l] 3.1 ±0.9 3.4 ±0.7 0.02
HDL cholesterol [mmol/l] 1.7 ±0.3 1.3 ±0.3 < 0.0001
Triglycerides [mmol/l] 1.2 ±0.8 2.3 ±1.2 < 0.0001
Estradiol [pg/ml] 59.8 ±65.2 44.7 ±40.8 NS
FSH [IU/l] 41.4 ±37.7 38.6 ±30.9 NS
Total testosterone [nmol/l] 1.06 ±0.56 1.30 ±0.83 0.05
Free testosterone [pmol/l] 12.9 ±7.8 22.36 ±16.7 0.001
Log free testosterone [nmol/l] 1.00 ±0.30 1.24 ±0.31 0.001
SHBG [nmol/l] 66.5 ±36.2 40.6 ±20.1 0.001
Log SHBG [nmol/l] 1.77 ±0.21 1.56 ±0.20 0.001
BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, ABPM – ambulatory blood pressure monitoring, 
FSH – follicle-stimulating hormone, SHBG – sex hormone binding globulin. P-value for Student’s t-test for independent variables.
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SHBG are strongly related to abdominal obesity. 
Data on the relationship between obesity and tes-
tosterone concentration in women are conflicting, 
with either an increase [9–12] or no change [13–
16] in BMI or waist circumference with increasing 
testosterone levels. The cross-sectional nature 
of most studies, including ours, rules out conclu-
sions on cause-and-effect relationships. There 
are data suggesting that testosterone levels can 
be modulated in response to metabolic signals, 
rather than the opposite. Adipose tissue, with its 
17b-hydroxysteroid dehydrogenase activity, has 
been suggested to be an important site of periph-
eral testosterone production [17, 18]. Moreover, 
studies analyzing the changes in testosterone af-
ter weight and body fat loss in overweight post-
menopausal women showed that weight loss was 
followed by a significant decrease in testosterone 
concentration [19, 20]. Conversely, studies exam-
ining the influence of testosterone treatment on 
changes in body composition showed an increase 
of body weight [21, 22]. These observations are 
further supported by the data on the influence of 
testosterone administration on fat metabolism. In 
Table II. Testosterone and SHBG concentration in pre- and postmenopausal women in relation to metabolic syn-
drome. Data are expressed as mean values ± standard deviations (SD)
Parameter Premenopausal women P-value Postmenopausal women P-value
Metabolic  
syndrome  
No
Metabolic  
syndrome  
Yes
Metabolic  
syndrome
No
Metabolic  
syndrome
Yes
N = 48 N = 41 N = 31 N = 32
Total testosterone [nmol/l] 1.19 ±0.53 1.50 ±0.88 0.04 0.93 ±0.56 1.14 ±0.71 0.07
Free testosterone [pmol/l] 13.6 ±7.9 22.2 ±13.0 0.001 12.3 ±7.0 22.4 ±9.0 0.001
Log free testosterone [nmol/l] 1.05 ±0.29 1.28 ±0.23 0.02 0.97 ±0.37 1.19 ±0.39 0.05
SHBG [nmol/l] 76.0 ±42.5 43.3 ±16.9 0.01 57.7 ±27.0* 38.2 ±22.1^ 0.02
Log SHBG [nmol/l] 1.82 ±0.21 1.62 ±0.16 0.005 1.71 ±0.21 1.52 ±0.23 0.01
Estradiol [pg/ml] 87.8 ±70.9 72.4 ±44.3 NS 19.5 ±17.3* 19.2 ±7.4^ NS
FSH [IU/l] 10.7 ±9.1 12.3 ±10.7 NS 74.9 ±26.9* 63.9 ±21.0^ NS
SHBG – sex hormone binding globulin, FSH – follicle-stimulating hormone. *P-value < 0.05 vs. premenopausal without MS, ^p-value < 0.05 
vs. premenopausal with MS. P-value for Student’s t-test for independent variables.
Table III. Metabolic syndrome components in quartiles of free testosterone concentration
Free testosterone 
quartiles
Waist  
circumference  
[cm]
Systolic blood 
pressure  
[mm Hg]
Triglyceride 
concentration 
[mmol/l]
HDL cholesterol 
concentration 
[mmol/l]
Glucose  
concentration 
[mmol/l]
Q1 80.0 ±8.2 151.4 ±10.9 1.06 ±0.34 1.70 ±0.34 5.00 ±0.47
Q2 84.6 ±9.7 152.6 ±15.6 1.21 ±0.54 1.58 ±0.33 4.91 ±0.58
Q3 86.2 ±9.9 154.6 ±17.8 1.86 ±0.60 1.47 ±0.24 5.11 ±0.27
Q4 92.0 ±8.7 158.1 ±13.9 1.94 ±0.76 1.28 ±0.23 5.43 ±0.55 
P-value 0.02 0.27 0.02 0.004 0.30
P-value for linear trend ANOVA analysis. 
Table IV. Metabolic syndrome components in quartiles of SHBG concentration
SHBG quartiles Waist  
circumference 
[cm]
Systolic blood 
pressure  
[mm Hg]
Triglyceride 
concentration 
[mmol/l]
HDL cholesterol 
concentration 
[mmol/l]
Glucose 
concentration 
[mmol/l]
Q1 92.1 ±8.6 159.9 ±13.1 1.87 ±0.60 1.28 ±0.24 5.39 ±0.80
Q2 87.4 ±10.3 157.3 ±16.4 1.74 ±0.50 1.50 ±0.26 5.04 ±0.30
Q3 83.6 ±8.7 150.0 ±17.1 1.27 ±0.36 1.55 ±0.33 5.11±0.67
Q4 79.7 ±8.0 151.2 ±10.8 1.02 ±0.52 1.71 ±0.34 4.79 ±0.34 
P-value 0.01 0.41 0.01 0.005 0.03
SHBG – sex hormone binding globulin. P-value for linear trend ANOVA analysis. 
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postmenopausal women oral administration of 
testosterone was associated with a  decrease in 
hormone-sensitive lipase expression in subcuta-
neous fat tissue, which may explain the shift of fat 
accumulation towards the visceral abdominal area 
in this group of patients [23].
Contrary to our prediction, we did not observe 
a  relationship between testosterone and blood 
pressure. The studies on associations between 
androgens and blood pressure in menopausal 
women brought inconsistent results. Similarly as 
in our group, Patel et al. [24] in a  large group of 
postmenopausal women found a significant rela-
tionship between increased testosterone and MS, 
but blood pressure values across quartiles of tes-
tosterone concentration were comparable. In con-
trast, in the population-based sample of women, 
a positive association between total testosterone 
and blood pressure in cross-sectional and longitu-
dinal analyses was shown [25]. It should be noted 
that in both in-vitro [26] and in-vivo [27] studies 
testosterone presents vasodilatory properties. 
This positive effect on vascular wall diameters can 
be attenuated by proatherogenic effects of testos-
terone, as observed in other studies. In vitro data 
suggest that testosterone may increase monocyte 
adhesion to the vascular endothelium [28]. Stud-
ies investigating the relation between testoster-
one and parameters of atherosclerosis in females 
have yielded contradictory results. Some studies 
found that higher levels of androgens and SHBG 
were associated with a  reduced level of athero-
sclerosis [29–31]; however, others found a  posi-
tive association between testosterone and indices 
of atherosclerosis [32, 33]. 
Our study gives further support to observations 
on the positive association between FT concentra-
tion and subclinical atherosclerosis.
There are only two studies examining the rela-
tionship of endogenous androgens with arterial 
stiffness in postmenopausal women. Creatsa et al. 
found that increased testosterone was associated 
with increase in arterial stiffness in women [34]. An-
other study in postmenopausal women on hemodi-
alysis indicated a  relationship between extremely 
low testosterone and increased vascular stiffness 
[35]. We did not find a relationship between arterial 
stiffness determined by carotid femoral pulse wave 
velocity and FT or SHBG. It cannot be excluded that 
the relationship between androgen concentration 
and arterial stiffness is U-shaped, but the limited 
data from observational studies in women do not 
allow us to draw conclusions. 
Table V. Multiple linear regression models to test 
the predictive value of free testosterone for pa-
rameters of left ventricular diastolic function and 
carotid intima-media thickness
Variable Multiple linear  
regression model
β P-value
IMT:
Free testosterone log  
(log [ng/ml])
0.34 0.009
Age [years] 0.41 0.003
SBP [mm Hg] 0.33 0.001
BMI [kg/m2] 0.13 0.19
Menopause (1 – yes, 0 – no) –0.05 0.97
Coefficient of determination R2 0.41
E/A:
Free testosterone log  
(log [ng/ml])
–0.19 0.05
Age [years] –0.23 0.07
SBP [mm Hg] –0.06 0.53
BMI [kg/m2] –0.23 0.03
Menopause (1 – yes, 0 – no) –0.22 0.09
Coefficient of determination R2 0.38
Figure 1. Number of metabolic syndrome compo-
nents and SHBG concentration
P-value for linear trend ANOVA analysis. 
SH
G
B 
[m
m
ol
/l
]
 1 2 3 4 5
          Number of MS components
120
100
80
60
40
20
0
–20
–40
–60
F = 2.6946
p = 0.03812
Figure 2. Number of metabolic syndrome compo-
nents and free testosterone concentration
P-value for linear trend ANOVA analysis. 
FT
 [N
G
/L
]
 1 2 3 4 5
          Number of MS components
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
F (4, 54) = 4.3784
p = 0.00387
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Increased left-ventricular mass is an important 
cardiovascular risk factor for morbidity and mor-
tality. Available data revealed that the changes in 
left-ventricular mass in response to age and hy-
pertrophic stimuli are different in men and women 
[36]. These differences are especially pronounced 
in people over 50 years old, in whom reproductive 
hormone concentrations have fallen. Only one 
study examined the relationship of sex hormones 
with heart structure in both sexes [37]. The au-
thors, using MRI, assessed the cardiac mass and 
right ventricular performance in a large cohort free 
from cardiovascular disease. Higher levels of tes-
tosterone and dehydroepiandrostenedione were 
associated with greater right ventricular mass in 
men. In women there was no correlation of testos-
terone with cardiac mass. Sex hormone binding 
globulin showed a  correlation with right ventric-
ular mass in both sexes, but this association was 
attenuated and not statistically significant when 
fully adjusted for covariates. Similar data were ob-
tained in our analyses. Testosterone did not show 
a relationship with left ventricular mass, while the 
relation of SHBG with left ventricular mass was 
BMI dependent.
In vitro studies show that estrogens have anti- 
proliferative effects on cardiac fibroblasts [38] and 
vascular smooth-muscle cells [39], while testoster-
one increases proliferation of myocytes and fibro-
blasts [40].
The shift in estrogen to androgen ratio during 
the menopausal transition in hypertensive sub-
jects characterized by the increased ventricular 
loading condition may predispose not only to 
changes in ventricular mass but also to ventricu-
lar compliance influencing diastolic function [41]. 
Analyzing the relationship between mitral inflow 
parameters, we found that FT was inversely relat-
ed to diastolic function. To our knowledge, this is 
the first report on the relation of androgens in per-
imenopausal women with left ventricular diastolic 
function.
The present study has several limitations. The 
cross-sectional character of the study means that 
it can explain only associations, not causality. Sec-
ond, as the study population consisted of mild and 
moderate hypertensive females, it is not enough 
to extrapolate our results to other groups. Third, 
we used automated electrochemiluminescence 
immunoassay for the quantification for total tes-
tosterone and SHBG, not liquid chromatography 
tandem mass spectrometry. Additionally, calcula-
tion of FT using the Vermeulen method may not 
correlate precisely with directly measured circu-
lating FT. However, immunoassay of total testos-
terone and calculation of FT are widely accepted 
methods used in large studies, since measure-
ment of total testosterone by mass spectrometry 
and FT by equilibrium dialysis is impractical.
In conclusion, in middle-aged hypertensive 
women independently of menopausal status free 
testosterone concentration is associated with in-
creased risk of metabolic syndrome. 
Free testosterone concentration is positively 
associated with parameters of subclinical athero-
sclerosis in the carotid artery and negatively with 
diastolic function of the left ventricle. 
Whether FT is a marker or mediator of cardio-
vascular disease in this population merits further 
investigation. 
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